Page 6 - பூமா உயிரி தொழில்நுட்பவியல் இன்க் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Posted on 7479 ONK Therapeutics Ltd, an innovative natural killer (NK) cell therapy company, today announced that it has appointed Hugh O’Dowd as Director and independent Non-executive Chairman of its Board of Directors. US-based Mr. O’Dowd brings significant experience and a background in the life sciences industry to the ONK Therapeutics’ Board in particular building organizations and commercialization of oncology therapeutics. His experience and strategic insights will be invaluable to ONK as it executes on its growth ambitions, progressing its novel, off-the-shelf, dual-targeted, natural killer (NK) cell therapy platform towards human clinical trials. Mr. O’Dowd currently serves as Non-executive Director on the Board of oncology development and commercialization company Puma Biotechnology, Inc (NASDAQ: PBYI). Until its acquisition by BioNTech SE in May 2020, Mr. O’Dowd served for four years as President,

San diegoUnited statesUnited kingdomLoyola universitySeamus mulliganIssac mankeAnthony killarneySue charlesEunan maguireHugh odowdMichael odwyerGeorge schlichTherapeutics ltdBoard of directors neon therapeutics incPuma biotechnology incTherapeutics inc